Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

85 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Increased myelotoxicity of idarubicin: is there a pharmacological basis? Results of a pharmacokinetic and an in vitro cytotoxicity study.
Kroschinsky F, Schleyer E, Renner U, Schimming C, Schimmelpfennig C, Bornhäuser M, Illmer T, Trümper L, Ehninger G, Schaich M. Kroschinsky F, et al. Among authors: schleyer e. Cancer Chemother Pharmacol. 2004 Jan;53(1):61-7. doi: 10.1007/s00280-003-0700-2. Epub 2003 Sep 3. Cancer Chemother Pharmacol. 2004. PMID: 12955471 Clinical Trial.
Pharmacokinetics and cellular uptake of imatinib and its main metabolite CGP74588.
le Coutre P, Kreuzer KA, Pursche S, Bonin Mv, Leopold T, Baskaynak G, Dörken B, Ehninger G, Ottmann O, Jenke A, Bornhäuser M, Schleyer E. le Coutre P, et al. Among authors: schleyer e. Cancer Chemother Pharmacol. 2004 Apr;53(4):313-23. doi: 10.1007/s00280-003-0741-6. Epub 2003 Dec 5. Cancer Chemother Pharmacol. 2004. PMID: 14658008
Imatinib mesylate for targeting the platelet-derived growth factor beta receptor in combination with fluorouracil and leucovorin in patients with refractory pancreatic, bile duct, colorectal, or gastric cancer--a dose-escalation Phase I trial.
Al-Batran SE, Atmaca A, Schleyer E, Pauligk C, Hosius C, Ehninger G, Jäger E. Al-Batran SE, et al. Among authors: schleyer e. Cancer. 2007 May 1;109(9):1897-904. doi: 10.1002/cncr.22622. Cancer. 2007. PMID: 17377918 Free article. Clinical Trial.
High-performance liquid chromatography method with ultraviolet detection for the quantification of the BCR-ABL inhibitor nilotinib (AMN107) in plasma, urine, culture medium and cell preparations.
Pursche S, Ottmann OG, Ehninger G, Schleyer E. Pursche S, et al. Among authors: schleyer e. J Chromatogr B Analyt Technol Biomed Life Sci. 2007 Jun 1;852(1-2):208-16. doi: 10.1016/j.jchromb.2007.01.019. Epub 2007 Jan 26. J Chromatogr B Analyt Technol Biomed Life Sci. 2007. PMID: 17291840
Conditioning with fludarabine and targeted busulfan for transplantation of allogeneic hematopoietic stem cells.
Bornhauser M, Storer B, Slattery JT, Appelbaum FR, Deeg HJ, Hansen J, Martin PJ, McDonald GB, Nichols WG, Radich J, Woolfrey A, Jenke A, Schleyer E, Thiede C, Ehninger G, Anasetti C. Bornhauser M, et al. Among authors: schleyer e. Blood. 2003 Aug 1;102(3):820-6. doi: 10.1182/blood-2002-11-3567. Epub 2003 Apr 3. Blood. 2003. PMID: 12676781 Free article. Clinical Trial.
85 results